# US 2016/0250252 A1 · Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250252 A1
- Document ID: US20160250252A1
- Status: Published application
- Kind: A1
- Application number: 14/957,705
- Filed: 2015-12-03
- Published: 2016-09-01
- Earliest claimed: 2014-12-03
- Assignees: University of Cincinnati
- Applicants: University of Cincinnati
- Inventors: Christy Holland; Jason Raymond; Jonathan Sutton
- Web page: https://patentgrep.com/patent/US20160250252A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 9/0009: {involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis}
- A61K 41/0028: {Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds}
- A61K 47/6911: {the form being a liposome}
- A61K 49/227: {Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric}
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1278: Post-loading, e.g. by ion or pH gradient
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Echogenic liposomes (ELIP) formulated with an at least partially pegylated phospholipid bi-layer shell, encapsulated nitric oxide, and encapsulated perfluorocarbon of the formula CxFy in a ratio of about 1:1 by volume, wherein X is greater than or equal to 3, are disclosed, along with methods for treating a patients suffering from cardiovascular disease by administering the ELIP at a site remote from the target diseased section, monitoring presence of the ELIP at the target diseased section, and administering ultrasound upon detection of presence such that bioactive NO is released at the target diseased section.

## Claims

### Claim 1

A method for treating a patient suffering from cardiovascular disease, the method comprising: delivering a liposome comprising nitric oxide (NO) locally to a target diseased section of the patient's vasculature; and releasing the NO at the target diseased section, wherein the liposome comprises NO in a ratio of from about 2:1 to about 1:2 by volume with a perfluorocarbon.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the ratio is about 1:1.

### Claim 3 (depends on 1)

The method according to claim 1, wherein delivering “locally” comprises administering the liposome comprising NO to the patient at a site remote from the target diseased section, monitoring for presence of the administered liposome at the target diseased section; and upon detection of presence, administering acoustic energy to the target diseased section thereby releasing a therapeutically effective amount of NO from the liposome to the target diseased section for a clinically relevant time frame.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the perflurocarbon has the formula CxFy and X is greater than or equal to three.

### Claim 5 (depends on 4)

The method according to claim 4, wherein X=3 and Y=8.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the liposome is pegylated.

### Claim 7

A method of preventing passive diffusion of NO from a liposome into a non-target tissue or fluid, the method comprising encapsulating the NO with a perfluorocarbon of the formula CxFy, wherein X is greater than or equal to three.

### Claim 8

An ex vivo method for assessing therapeutic suitability of a liposome comprising NO and a perfluorocarbon in a volume ratio, the method comprising (i) administering the liposome to a segment of vasculature while exposing the section of vasculature to ultrasound; and (ii) simultaneously measuring at least one indicator of ex vivo vascular tone and at least one indicator of acoustic response.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the at least one indicator of ex vivo vascular tone comprises a measurement of arterial tension with a force transducer.

### Claim 10 (depends on 8)

The method according to claim 8 wherein the at least one indicator of acoustic response is selected from echogenicity, nonlinear scattering, and combinations thereof.

### Claim 11

A method of manufacturing an echogenic liposome effective for ultrasound-mediated drug release, the method comprising: providing a liposomal emulsion comprising phospholipids, injecting a volume ratio of nitric oxide and a perfluorocarbon of the formula CxFy into the liposomal emulsion; agitating the emulsion; adjusting the temperature of the liposome formulation to room temperature, wherein freezing of the liposomal emulsion is avoided.

### Claim 12 (depends on 11)

The method according to claim 11, wherein X is at least 3 and the volume ratio is about 1:1.

### Claim 13 (depends on 11)

The method according to claim 11, wherein the liposome emulsion further comprises long-chain PEG, and short-chain PEG.

### Claim 14 (depends on 11)

The method according to claim 11 wherein the phospholipids consist of one or more of nonionic and anionic phospholipids.

### Claim 15

A method of quantitatively assessing an agent or an amount of an agent for efficacy in ultrasound-mediated drug release, the method comprising providing a viable segment of arterial vasculature mounted in a physiological buffer solution; coupling the arterial segment to an isometric force transducer; infusing agent-loaded liposome into a lumen of the segment while exposing the arterial segment to ultrasound; and monitoring at least one indicator of vascular tone, wherein an agent or an amount of an agent is assessed as exhibiting efficacy if a decrease in vascular tone of the arterial segment is indicated.

### Claim 16 (depends on 15)

The method according to claim 15, wherein at least one indicator of vascular tone comprises measurement of arterial tension with a force transducer.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the arterial segment is exposed to between 1 and 30 MHz ultrasound at a peak-to-peak acoustic pressure of less than 0.5 MPa.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the peak-to-peak acoustic pressure is 0.34 MPa.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the artery is exposed to 1-MHz ultrasound at a peak-to-peak acoustic pressure of 0.34 MPa.

### Claim 20 (depends on 14)

The method according to claim 14, wherein the ultrasound is pulsed.

### Claim 21 (depends on 15)

The method according to claim 15, wherein a confocal point is positioned at an axial center of a ring of the carotid artery and a calibrated 1-MHz transducer is confocally aligned with a 7.5 MHz passive cavitation detector using an ultrasonic pulser receiver such that the entire carotid artery segment is exposed to ultrasound while cavitation emissions are detected from the lumen.

### Claim 22

An echogenic liposome comprising an at least partially pegylated phospholipid bi-layer shell, encapsulated nitric oxide, and encapsulated perfluorocarbon of the formula CxFy, wherein X is greater than or equal to 3, further wherein the ratio of NO to CxFy is about 1:1 by volume.

### Claim 23 (depends on 22)

An echogenic liposome according to claim 22, wherein the at least partially pegylated phospholipid bi-layer shell comprises dipalmitoylphosphatidylholine (DPPC), L-α-phosphatidylcholine (EggPC), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG2000), 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DPPG), and CH in a molar ratio of 28:43:6:8:15.
